Farnaz Naeemikia

Farnaz Naeemikia

Auto-generated profile, based on publicly available information

Farnaz Naeemikia

Department of Biomedical Engineering, 211 Wartik Lab, The Pennsylvania State University, University Park, PA 16802, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021 in iScience
Verified
Journal Article
Open access
HIHaider Inam
Haider Inam
ISIvan Sokirniy
Ivan Sokirniy
YRYiyun Rao
Yiyun Rao
ASAnushka Shah
Anushka Shah
FNFarnaz Naeemikia
Farnaz Naeemikia
JPJustin R. Pritchard
Justin R. Pritchard
Genomic data can facilitate personalized treatment decisions by enabling therapeutic hypotheses in individual patients. Mutual exclusivity has been an empirically useful signal for identifying activating mutations that respond to single agent targeted therapies. However, a low mutation frequency can underpower this signal for rare variants. We develop a resampling based method for the direct pairwise comparison of conditional selection between sets of gene pairs. We apply this method to a transcript variant of anaplastic lymphoma kinase (ALK) in melanoma, termed ALKATI that was suggested to predict sensitivity to ALK inhibitors and we find that it is not mutually exclusive with key melanoma oncogenes. Furthermore, we find that ALKATI is not likely to be sufficient for cellular transformation or growth, and it does not predict single agent therapeutic dependency. Our work strongly disfavors the role of ALKATI as a targetable oncogenic driver that might be sensitive to single agent ALK treatment.